The monosodium vaccine against coronavirus Janssen of the American pharmaceutical group Johnson & Johnson was approved today (28/05) by Great Britain. According to the country’s Ministry of Health, with this development they added a quarter vaccine in the “quiver” for the… battle against the pandemic.
This vaccine, which today received the approval of the British Regulatory Authority MHRA, will be added to those of Pfizer, AstraZeneca and Moderna already used in the country.
The Ministry of Health stated that the government has decided to order 20 million doses of the vaccine, modifying an initial order for 30 million installments.
Britain has given two-thirds of the population the first dose of a COVID-19 vaccine, and the government has invoked the unprecedented “scale and pace” of vaccinations to justify its decision to reduce its order to 20 million. installments from the initial order of 30 million installments.
“As Janssen is a single-dose vaccine, it will play an important role in the coming months as we redouble our efforts to encourage everyone to inject and possibly start an aid program later this year,” said Health Minister Matt Hancock. the Athenian-Macedonian News Agency.
Her vaccine Johnson & Johnson has already been approved in the US and the European Union, where reports of rare cases of blood clots are being reviewed. It uses a similar viral vector technology to that of AstraZeneca and the University of Oxford, where similar cases of thrombi have been reported.
The United Kingdom has recommended that an alternative AstraZeneca vaccine be offered to people under the age of 40, and the government has said that the Joint Vaccination and Immunization Committee (JCVI) will also give an opinion on how the J&J vaccine should be used.
The government said the vaccine would be available later this year. There are reports that J&J expects it will not meet its vaccine delivery targets in the EU this quarter.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
